Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11303MR)

This product GTTS-WQ11303MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11303MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ199MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ13608MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ15821MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ13293MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ9872MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ6625MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ8583MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ5509MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW